Fertility Preservation in Women with Cervical Cancer

Abstract

Cervical cancer (CC) is one of the most common malignancies affecting young women of childbearing age, making fertility preservation (FP) a pivotal consideration in its management. The feasibility of FP techniques depends on the cancer stage and oncological treatments. In early-stage CC, fertility-sparing surgery can be offered for young patients wishing to preserve fertility without compromising oncological safety. Neoadjuvant chemotherapy followed by fertility-sparing surgery is an alternative for patients with nonmetastatic locally advanced disease and negative lymph node status. Nevertheless, for patients with locally advanced disease requiring radical hysterectomy or pelvic radiotherapy, FP can be performed using oocyte, embryo, or ovarian tissue cryopreservation. For these patients, future pregnancy is possible through surrogacy. Recently, uterine transposition has been proposed as an alternative to preserve uterine anatomy to prevent uterine radio-induced damage and avoid surrogacy. This review provides a comprehensive overview of the FP options available for young patients with CC.

Keywords

fertility preservation - fertility-sparing surgery - cervical cancer

Publikationsverlauf

Artikel online veröffentlicht:
01. August 2025

• References

• 1 Cervical cancer [Internet]. [cité 24 déc 2024]. Disponible sur: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
• 2 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021; 71 (03) 209-249
• 3 Das M. WHO launches strategy to accelerate elimination of cervical cancer. Lancet Oncol 2021; 22 (01) 20-21
• 4 Anderson RA, Amant F, Braat D. et al; ESHRE Guideline Group on Female Fertility Preservation. ESHRE guideline: female fertility preservation. Hum Reprod Open 2020; 2020 (04) hoaa052
• 5 Cibula D, Raspollini MR, Planchamp F. et al. ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer - update 2023. Int J Gynecol Cancer 2023; 33 (05) 649-666
• 6 Abu-Rustum NR, Yashar CM, Bean S. et al. NCCN guidelines insights: cervical cancer, version 1.2020. J Natl Compr Canc Netw 2020; 18 (06) 660-666
• 7 Morice P, Scambia G, Abu-Rustum NR. et al. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. Lancet Oncol 2024; 25 (11) e602-e610
• 8 Nezhat C, Roman RA, Rambhatla A, Nezhat F. Reproductive and oncologic outcomes after fertility-sparing surgery for early stage cervical cancer: a systematic review. Fertil Steril 2020; 113 (04) 685-703
• 9 De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010; 376 (9744) 911-921
• 10 Pereira N, Voskuilen-Gonzalez A, Hancock K, Lekovich JP, Schattman GL, Rosenwaks Z. Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes. Reprod Biomed Online 2017; 35 (04) 400-406
• 11 Gotschel F, Sonigo C, Becquart C, Sellami I, Mayeur A, Grynberg M. New insights on in vitro maturation of oocytes for fertility preservation. Int J Mol Sci 2024; 25 (19) 10605
• 12 Salman L, Covens A. Fertility preservation in cervical cancer-treatment strategies and indications. Curr Oncol 2024; 31 (01) 296-306
• 13 van der Plas RCJ, Bos AME, Jürgenliemk-Schulz IM, Gerestein CG, Zweemer RP. Fertility-sparing surgery and fertility preservation in cervical cancer: the desire for parenthood, reproductive and obstetric outcomes. Gynecol Oncol 2021; 163 (03) 538-544
• 14 Marklund A, Jiang Y, Röjlar H. et al. The complexity and challenges of fertility preservation in women with cervix cancer-A prospective cohort study reporting on reproductive outcome and overall survival. Acta Obstet Gynecol Scand 2025; 104 (01) 86-94
• 15 Anderson RA, Brewster DH, Wood R. et al. The impact of cancer on subsequent chance of pregnancy: a population-based analysis. Hum Reprod 2018; 33 (07) 1281-1290
• 16 Baiocchi G, Mantoan H, Chen MJ, Faloppa CC. Uterine transposition after radical trachelectomy. Gynecol Oncol 2018; 150 (02) 387-388
• 17 Baiocchi G, Vieira M, Moretti-Marques R. et al. Uterine transposition for gynecological cancers. Int J Gynecol Cancer 2021; 31 (03) 442-446
• 18 Marques RM, Tsunoda AT, Dias RS, Pimenta JM, Linhares JC, Ribeiro R. Robotic uterine transposition for a cervical cancer patient with pelvic micrometastases after conization and pelvic lymphadenectomy. Int J Gynecol Cancer 2020; 30 (06) 898-899
• 19 Ribeiro R, Rebolho JC, Tsumanuma FK, Brandalize GG, Trippia CH, Saab KA. Uterine transposition: technique and a case report. Fertil Steril 2017; 108 (02) 320-324.e1
• 20 Moretti-Marques R, Franca IB, de Cillo PE. et al. First birth after uterine transposition in low-volume lymph node metastasis of cervical cancer: A long journey for success. J Surg Oncol 2024; 130 (04) 896-903
• 21 Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet 2021; 155 (suppl 1): 28-44
• 22 Olawaiye AB, Baker TP, Washington MK, Mutch DG. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. Cancer J Clin 2021; 71 (04) 287-298